Screener
Oruka Therapeutics, Inc. ORKA Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Related party accounts payable and other current liabilities | 2,995 | (5,205) |
| Net cash used in operating activities | (23,578) | (20,869) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (73) | (13) |
| Purchases of marketable securities | (90,834) | (44,290) |
| Proceeds from maturities of marketable securities | 76,470 | 87,169 |
| Net cash (used in) provided by investing activities | (14,437) | 42,866 |
| Cash flows from financing activities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s payments to acquire property, plant, and equipment?
- Oruka Therapeutics, Inc. (ORKA) reported payments to acquire property, plant, and equipment of $73K in Q1 2026.
- How has Oruka Therapeutics, Inc.'s payments to acquire property, plant, and equipment changed year-over-year?
- Oruka Therapeutics, Inc.'s payments to acquire property, plant, and equipment increased by 461.5% year-over-year, from $13K to $73K.
- What is the long-term trend for Oruka Therapeutics, Inc.'s payments to acquire property, plant, and equipment?
- Over 2 years (2021 to 2025), Oruka Therapeutics, Inc.'s payments to acquire property, plant, and equipment has grown at a 120.5% compound annual growth rate (CAGR), from $43K to $209K.
- What does payments to acquire property, plant, and equipment mean?
- Represents cash outflows used to purchase tangible long-term assets necessary for business operations. This metric serves as a primary indicator of capital expenditure intensity and investment in future production or research capacity.
Ask your AI about Oruka Therapeutics, Inc.'s payments to acquire property, plant, and equipment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude